{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:19:06Z","timestamp":1790734746362,"version":"4.1.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Epigenetic changes are present in all human cancers and are responsible for switching on or off genes, thus controlling tumor cell transcriptome. These changes occur through DNA methylation, histone modifiers and readers, chromatin remodelers, and microRNAs. The histone H3 methyl-transferase EZH2 gene is overexpressed in several cancer types, including adrenocortical carcinoma (ACC), a rare cancer still lacking a targeted therapy. EZH2 inhibitors (EZH2i) have been tested in several clinical trials, but their effectiveness was limited by the toxic effects of the therapeutic doses. We tested several EZH2i on ACC cells, and observed a significant reduction in cell growth only with doses much higher than those required to prevent H3 methylation. We found that all tested EZH2i doses affected lipid metabolism genes, ROS, and glutathione production. Transcript changes correlated with metabolic data, which suggested the effects of EZH2i on ferroptosis. We found that EZH2i dose-dependently increased SLC7A11\/glutathione axis and glutathione peroxidase-4 (GPX4), required to counteract lipid peroxidation and ferroptosis. A GPX4 inhibitor synergized with EZH2i, making low doses - which otherwise do not affect cell viability - able to significantly reduce ACC cell growth in vitro and in vivo. Importantly, we found that the anti-ferroptosis defense mechanism induced by EZH2i is a common response for several aggressive tumor phenotypes, uncovering a general co-targetable mechanism that could limit EZH2i effectiveness. Correcting this antioxidant response by ferroptosis inducers may be a new combination therapy that will easily find clinical applications.<\/jats:p>","DOI":"10.1038\/s41419-025-07607-y","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T03:30:36Z","timestamp":1744601436000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A targetable antioxidant defense mechanism to EZH2 inhibitors enhances tumor cell vulnerability to ferroptosis"],"prefix":"10.1038","volume":"16","author":[{"given":"Marta C.","family":"Nocito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constanze","family":"Hantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio M.","family":"Lerario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2401-6181","authenticated-orcid":false,"given":"Fabrizio","family":"Mastrorocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"De Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4359-4403","authenticated-orcid":false,"given":"Clara","family":"Musicco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida D.","family":"Perrotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariafrancesca","family":"Scalise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9818-6621","authenticated-orcid":false,"given":"Cesare","family":"Indiveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5559-5556","authenticated-orcid":false,"given":"Sergio","family":"Giannattasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Val","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6362-5396","authenticated-orcid":false,"given":"Marilena","family":"Lanzino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Pezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Casaburi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8966-350X","authenticated-orcid":false,"given":"Rosa","family":"Sirianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"key":"7607_CR1","first-page":"1","volume":"2023","author":"C Ghosh","year":"2023","unstructured":"Ghosh C, Hu J, Kebebew E. Advances in translational research of the rare cancer type adrenocortical carcinoma. Nat Rev Cancer. 2023;2023:1\u201320.","journal-title":"Nat Rev Cancer"},{"key":"7607_CR2","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1210\/en.2015-1367","volume":"156","author":"S Sbiera","year":"2015","unstructured":"Sbiera S, Leich E, Liebisch G, Sbiera I, Schirbel A, Wiemer L, et al. Mitotane inhibits sterol-O-acyl transferase 1 triggering lipid-mediated endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells. Endocrinology. 2015;156:3895\u2013908.","journal-title":"Endocrinology"},{"key":"7607_CR3","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1210\/en.2015-2052","volume":"157","author":"CR LaPensee","year":"2016","unstructured":"LaPensee CR, Mann JE, Rainey WE, Crudo V, Hunt SW, Hammer GD. ATR-101, a selective and potent inhibitor of acyl-CoA acyltransferase 1, induces apoptosis in H295R adrenocortical cells and in the adrenal cortex of dogs. Endocrinology. 2016;157:1775\u201388.","journal-title":"Endocrinology"},{"key":"7607_CR4","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s10637-020-00899-1","volume":"38","author":"DC Smith","year":"2020","unstructured":"Smith DC, Kroiss M, Kebebew E, Habra MA, Chugh R, Schneider BJ, et al. A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma. Investig N Drugs. 2020;38:1421\u20139.","journal-title":"Investig N Drugs"},{"key":"7607_CR5","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1210\/jc.2008-1456","volume":"94","author":"FM Barlaskar","year":"2009","unstructured":"Barlaskar FM, Spalding AC, Heaton JH, Kuick R, Kim AC, Thomas DG, et al. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J Clin Endocrinol Metab. 2009;94:204\u201312.","journal-title":"J Clin Endocrinol Metab"},{"key":"7607_CR6","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","volume":"16","author":"M Fassnacht","year":"2015","unstructured":"Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015;16:426\u201335.","journal-title":"Lancet Oncol"},{"key":"7607_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ccr.2012.06.008","volume":"22","author":"JS You","year":"2012","unstructured":"You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same coin?. Cancer Cell. 2012;22:9\u201320.","journal-title":"Cancer Cell"},{"key":"7607_CR8","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.1111\/jcmm.16317","volume":"25","author":"A Chimento","year":"2021","unstructured":"Chimento A, De Luca A, Nocito MC, Sculco S, Avena P, La Padula D, et al. SIRT1 is involved in adrenocortical cancer growth and motility. J Cell Mol Med. 2021;25:3856\u201369.","journal-title":"J Cell Mol Med"},{"key":"7607_CR9","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41573-020-00108-x","volume":"20","author":"KP Bhat","year":"2021","unstructured":"Bhat KP, \u00dcmit Kaniskan H, Jin J, Gozani O. Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021;20:265\u201386.","journal-title":"Nat Rev Drug Discov"},{"key":"7607_CR10","first-page":"2789","volume":"25","author":"C Drelon","year":"2016","unstructured":"Drelon C, Berthon A, Mathieu M, Ragazzon B, Kuick R, Tabbal H, et al. EZH2 is overexpressed in adrenocortical carcinoma and is associated with disease progression. Hum Mol Genet. 2016;25:2789\u2013800.","journal-title":"Hum Mol Genet"},{"key":"7607_CR11","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/s41416-019-0538-y","volume":"121","author":"H Tabbal","year":"2019","unstructured":"Tabbal H, Septier A, Mathieu M, Drelon C, Rodriguez S, Djari C, et al. EZH2 cooperates with E2F1 to stimulate expression of genes involved in adrenocortical carcinoma aggressiveness. Br J Cancer. 2019;121:384\u201394.","journal-title":"Br J Cancer"},{"key":"7607_CR12","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1158\/1535-7163.MCT-09-0013","volume":"8","author":"TB Miranda","year":"2009","unstructured":"Miranda TB, Cortez CC, Yoo CB, Liang G, Abe M, Kelly TK, et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther. 2009;8:1579\u201388.","journal-title":"Mol Cancer Ther"},{"key":"7607_CR13","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1002\/tcr.201800091","volume":"18","author":"R Fioravanti","year":"2018","unstructured":"Fioravanti R, Stazi G, Zwergel C, Valente S, Mai A. Six years (2012\u20132018) of researches on catalytic EZH2 inhibitors: the boom of the 2-pyridone compounds. Chem Rec. 2018;18:1818\u201332.","journal-title":"Chem Rec"},{"key":"7607_CR14","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature11606","volume":"492","author":"MT McCabe","year":"2012","unstructured":"McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012;492:108\u201312.","journal-title":"Nature"},{"key":"7607_CR15","doi-asserted-by":"publisher","first-page":"7331","DOI":"10.1158\/1078-0432.CCR-18-4121","volume":"25","author":"TA Yap","year":"2019","unstructured":"Yap TA, Winter JN, Giulino-Roth L, Longley J, Lopez J, Michot JM, et al. Phase I study of the novel enhancer of zeste homolog 2 (EZH2) inhibitor GSK2816126 in patients with advanced hematologic and solid tumors. Clin Cancer Res. 2019;25:7331\u20139.","journal-title":"Clin Cancer Res"},{"key":"7607_CR16","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1021\/ml3003346","volume":"3","author":"SK Verma","year":"2012","unstructured":"Verma SK, Tian X, Lafrance LV, Duquenne C, Suarez DP, Newlander KA, et al. Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2. ACS Med Chem Lett. 2012;3:1091\u20136.","journal-title":"ACS Med Chem Lett"},{"key":"7607_CR17","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1158\/1535-7163.MCT-13-0773","volume":"13","author":"SK Knutson","year":"2014","unstructured":"Knutson SK, Kawano S, Minoshima Y, Warholic NM, Huang KC, Xiao Y, et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther. 2014;13:842\u201354.","journal-title":"Mol Cancer Ther"},{"key":"7607_CR18","doi-asserted-by":"publisher","first-page":"8577","DOI":"10.1074\/jbc.RA118.006871","volume":"294","author":"NKH Yiew","year":"2019","unstructured":"Yiew NKH, Greenway C, Zarzour A, Ahmadieh S, Goo B, Kim D, et al. Enhancer of zeste homolog 2 (EZH2) regulates adipocyte lipid metabolism independent of adipogenic differentiation: Role of apolipoprotein E. J Biol Chem. 2019;294:8577.","journal-title":"J Biol Chem"},{"key":"7607_CR19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10549-010-0982-0","volume":"127","author":"A Hayden","year":"2010","unstructured":"Hayden A, Johnson PWM, Packham G, Crabb SJ. S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition. Breast Cancer Res Treat. 2010;127:109\u201319.","journal-title":"Breast Cancer Res Treat"},{"key":"7607_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103872","volume":"77","author":"T Zhang","year":"2022","unstructured":"Zhang T, Guo Z, Huo X, Gong Y, Li C, Huang J, et al. Dysregulated lipid metabolism blunts the sensitivity of cancer cells to EZH2 inhibitor. eBioMedicine. 2022;77:103872.","journal-title":"eBioMedicine"},{"key":"7607_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103916","volume":"77","author":"Y Wang","year":"2022","unstructured":"Wang Y. Fatty acid metabolism and drug resistance to EZH2 inhibition. eBioMedicine. 2022;77:103916.","journal-title":"eBioMedicine"},{"key":"7607_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216119","volume":"559","author":"J Lee","year":"2023","unstructured":"Lee J, Roh J-L. Targeting GPX4 in human cancer: Implications of ferroptosis induction for tackling cancer resilience. Cancer Lett. 2023;559:216119.","journal-title":"Cancer Lett"},{"key":"7607_CR23","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060\u201372.","journal-title":"Cell"},{"key":"7607_CR24","doi-asserted-by":"publisher","first-page":"22269","DOI":"10.1073\/pnas.1912700116","volume":"116","author":"A Belavgeni","year":"2019","unstructured":"Belavgeni A, Bornstein SR, Von M\u00e4ssenhausen A, Tonnus W, Stumpf J, Meyer C, et al. Exquisite sensitivity of adrenocortical carcinomas to induction of ferroptosis. Proc Natl Acad Sci USA. 2019;116:22269\u201374.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7607_CR25","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.3390\/cancers13164200","volume":"13","author":"C Bothou","year":"2021","unstructured":"Bothou C, Sharma A, Oo A, Kim B, Perge P, Igaz P, et al. Novel insights into the molecular regulation of ribonucleotide reductase in adrenocortical carcinoma treatment. Cancers. 2021;13:4200.","journal-title":"Cancers"},{"key":"7607_CR26","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S1043-2760(05)80014-1","volume":"4","author":"KL Parker","year":"1993","unstructured":"Parker KL, Schimmer BP. Transcriptional regulation of the adrenal steroidogenic enzymes. Trends Endocrinol Metab. 1993;4:46\u201350.","journal-title":"Trends Endocrinol Metab"},{"key":"7607_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42003-018-0020-z","volume":"1","author":"T Baba","year":"2018","unstructured":"Baba T, Otake H, Inoue M, Sato T, Ishihara Y, Moon JY, et al. Ad4BP\/SF-1 regulates cholesterol synthesis to boost the production of steroids. Commun Biol. 2018;1:1\u20139.","journal-title":"Commun Biol"},{"key":"7607_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms4634","volume":"5","author":"T Baba","year":"2014","unstructured":"Baba T, Otake H, Sato T, Miyabayashi K, Shishido Y, Wang CY, et al. Glycolytic genes are targets of the nuclear receptor Ad4BP\/SF-1. Nat Commun. 2014;5:1\u201313.","journal-title":"Nat Commun"},{"key":"7607_CR29","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.redox.2015.08.006","volume":"6","author":"R Mashima","year":"2015","unstructured":"Mashima R, Okuyama T. The role of lipoxygenases in pathophysiology; new insights and future perspectives. Redox Biol. 2015;6:297\u2013310.","journal-title":"Redox Biol"},{"key":"7607_CR30","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/S1388-1981(01)00100-7","volume":"1531","author":"P Spiteller","year":"2001","unstructured":"Spiteller P, Kern W, Reiner J, Spiteller G. Aldehydic lipid peroxidation products derived from linoleic acid. Biochim Biophys Acta Mol Cell Biol Lipids. 2001;1531:188\u2013208.","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"7607_CR31","doi-asserted-by":"publisher","first-page":"e0210013","DOI":"10.1371\/journal.pone.0210013","volume":"14","author":"T Chiba Id","year":"2019","unstructured":"Chiba Id T, Nakahara T, Kohda F, Id TI, Manabe M, Furue M. Measurement of trihydroxy-linoleic acids in stratum corneum by tape-stripping: possible biomarker of barrier function in atopic dermatitis. PLoS ONE. 2019;14:e0210013.","journal-title":"PLoS ONE"},{"key":"7607_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-023-05601-w","volume":"14","author":"JS Park","year":"2023","unstructured":"Park JS, Kim DH, Choi HI, Kim CS, Bae EH, Ma SK, et al. 3-Carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) induces cell death through ferroptosis and acts as a trigger of apoptosis in kidney cells. Cell Death Dis. 2023;14:1\u201311.","journal-title":"Cell Death Dis"},{"key":"7607_CR33","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.freeradbiomed.2008.05.004","volume":"45","author":"CC Winterbourn","year":"2008","unstructured":"Winterbourn CC, Hampton MB. Thiol chemistry and specificity in redox signaling. Free Radic Biol Med. 2008;45:549\u201361.","journal-title":"Free Radic Biol Med"},{"key":"7607_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-35059-x","volume":"13","author":"A Verma","year":"2022","unstructured":"Verma A, Singh A, Singh MP, Nengroo MA, Saini KK, Satrusal SR, et al. EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis. Nat Commun. 2022;13:1\u201322.","journal-title":"Nat Commun"},{"key":"7607_CR35","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nm.4036","volume":"22","author":"KH Kim","year":"2016","unstructured":"Kim KH, Roberts CWM. Targeting EZH2 in cancer. Nat Med. 2016;22:128\u201334.","journal-title":"Nat Med"},{"key":"7607_CR36","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.cell.2018.08.058","volume":"175","author":"X Huang","year":"2018","unstructured":"Huang X, Yan J, Zhang M, Wang Y, Chen Y, Fu X, et al. Targeting epigenetic crosstalk as a therapeutic strategy for EZH2-aberrant solid tumors. Cell. 2018;175:186\u2013199.e19.","journal-title":"Cell"},{"key":"7607_CR37","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/s41556-023-01136-6","volume":"25","author":"K Papsdorf","year":"2023","unstructured":"Papsdorf K, Miklas JW, Hosseini A, Cabruja M, Morrow CS, Savini M, et al. Lipid droplets and peroxisomes are co-regulated to drive lifespan extension in response to mono-unsaturated fatty acids. Nat Cell Biol. 2023;25:672.","journal-title":"Nat Cell Biol"},{"key":"7607_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.577420","volume":"10","author":"LP Fern\u00e1ndez","year":"2020","unstructured":"Fern\u00e1ndez LP, G\u00f3mez de Cedr\u00f3n M, Ram\u00edrez de Molina A. Alterations of lipid metabolism in cancer: implications in prognosis and treatment. Front Oncol. 2020;10:577420.","journal-title":"Front Oncol"},{"key":"7607_CR39","doi-asserted-by":"publisher","first-page":"25382","DOI":"10.1074\/jbc.M114.580662","volume":"289","author":"LR Edmunds","year":"2014","unstructured":"Edmunds LR, Sharma L, Kang A, Lu J, Vockley J, Basu S, et al. c-Myc programs fatty acid metabolism and dictates acetyl-CoA abundance and fate. J Biol Chem. 2014;289:25382.","journal-title":"J Biol Chem"},{"key":"7607_CR40","doi-asserted-by":"publisher","first-page":"6027","DOI":"10.1073\/pnas.111138698","volume":"98","author":"J Ou","year":"2001","unstructured":"Ou J, Tu H, Shan B, Luk A, DeBose-Boyd RA, Bashmakov Y, et al. Unsaturated fatty acids inhibit transcription of the sterol regulatory element-binding protein-1c (SREBP-1c) gene by antagonizing ligand-dependent activation of the LXR. Proc Natl Acad Sci USA. 2001;98:6027\u201332.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7607_CR41","doi-asserted-by":"publisher","first-page":"219","DOI":"10.5487\/TR.2017.33.3.219","volume":"33","author":"K Seo","year":"2017","unstructured":"Seo K, Shin SM. Induction of Lipin1 by ROS-dependent SREBP-2 activation. Toxicol Res. 2017;33:219\u201324.","journal-title":"Toxicol Res"},{"key":"7607_CR42","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1152\/physrev.00019.2018","volume":"99","author":"MC Meinsohn","year":"2019","unstructured":"Meinsohn MC, Smith OE, Bertolin K, Murphy BD. The orphan nuclear receptors steroidogenic factor-1 and liver receptor homolog-1: Structure, regulation, and essential roles in mammalian reproduction. Physiol Rev. 2019;99:1249\u201379.","journal-title":"Physiol Rev"},{"key":"7607_CR43","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1210\/me.2007-0120","volume":"21","author":"M Doghman","year":"2007","unstructured":"Doghman M, Karpova T, Rodrigues GA, Arhatte M, De Moura J, Cavalli LR, et al. Increased steroidogenic factor-1 dosage triggers adrenocortical cell proliferation and cancer. Mol Endocrinol. 2007;21:2968\u201387.","journal-title":"Mol Endocrinol"},{"key":"7607_CR44","doi-asserted-by":"publisher","first-page":"4449","DOI":"10.1021\/bi00181a003","volume":"33","author":"BA Wagner","year":"1994","unstructured":"Wagner BA, Burns CP, Buettner GR. Free radical-mediated lipid peroxidation in cells: oxidizability is a function of cell lipid bis-allylic hydrogen content. Biochemistry. 1994;33:4449\u201353.","journal-title":"Biochemistry"},{"key":"7607_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-23408-0","volume":"8","author":"E Agmon","year":"2018","unstructured":"Agmon E, Solon J, Bassereau P, Stockwell BR. Modeling the effects of lipid peroxidation during ferroptosis on membrane properties. Sci Rep. 2018;8:1\u201311.","journal-title":"Sci Rep."},{"key":"7607_CR46","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nature23007","volume":"547","author":"VS Viswanathan","year":"2017","unstructured":"Viswanathan VS, Ryan MJ, Dhruv HD, Gill S, Eichhoff OM, Seashore-Ludlow B, et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. 2017;547:453\u20137.","journal-title":"Nature"},{"key":"7607_CR47","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1021\/ja907716f","volume":"132","author":"PY Yang","year":"2010","unstructured":"Yang PY, Liu K, Ngai MH, Lear MJ, Wenk MR, Yao SQ. Activity-based proteome profiling of potential cellular targets of orlistat - An FDA-approved drug with anti-tumor activities. J Am Chem Soc. 2010;132:656\u201366.","journal-title":"J Am Chem Soc"},{"key":"7607_CR48","doi-asserted-by":"publisher","first-page":"5355","DOI":"10.1158\/0008-5472.CAN-19-0369","volume":"79","author":"L Tesfay","year":"2019","unstructured":"Tesfay L, Paul BT, Konstorum A, Deng Z, Cox AO, Lee J, et al. Stearoyl-CoA desaturase 1 protects ovarian cancer cells from ferroptotic cell death. Cancer Res. 2019;79:5355\u201366.","journal-title":"Cancer Res"},{"key":"7607_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2021.102006","volume":"43","author":"G Luis","year":"2021","unstructured":"Luis G, Godfroid A, Nishiumi S, Cimino J, Blacher S, Maquoi E, et al. Tumor resistance to ferroptosis driven by stearoyl-CoA desaturase-1 (SCD1) in cancer cells and Fatty Acid Biding Protein-4 (FABP4) in tumor microenvironment promote tumor recurrence. Redox Biol. 2021;43:102006.","journal-title":"Redox Biol"},{"key":"7607_CR50","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.chembiol.2018.11.016","volume":"26","author":"L Magtanong","year":"2019","unstructured":"Magtanong L, Ko PJ, To M, Cao JY, Forcina GC, Tarangelo A, et al. Exogenous monounsaturated fatty acids promote a ferroptosis-resistant cell state. Cell Chem Biol. 2019;26:420\u2013432.e9.","journal-title":"Cell Chem Biol"},{"key":"7607_CR51","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1158\/0008-5472.CAN-13-1803","volume":"74","author":"Y Yang","year":"2014","unstructured":"Yang Y, Yee D. IGF-I regulates redox status in breast cancer cells by activating the amino acid transport molecule xC-. Cancer Res. 2014;74:2295\u2013305.","journal-title":"Cancer Res"},{"key":"7607_CR52","doi-asserted-by":"publisher","first-page":"770857","DOI":"10.3389\/fgene.2021.770857","volume":"12","author":"J He","year":"2021","unstructured":"He J, Ding H, Li H, Pan Z, Chen Q. Intra-tumoral expression of SLC7A11 is associated with immune microenvironment, drug resistance, and prognosis in cancers: a Pan-cancer analysis. Front Genet. 2021;12:770857.","journal-title":"Front Genet"},{"key":"7607_CR53","doi-asserted-by":"publisher","first-page":"79292","DOI":"10.18632\/oncotarget.12685","volume":"7","author":"C Hantel","year":"2016","unstructured":"Hantel C, Shapiro I, Poli G, Chiapponi C, Bidlingmaier M, Reincke M, et al. Targeting heterogeneity of adrenocortical carcinoma: evaluation and extension of preclinical tumor models to improve clinical translation. Oncotarget. 2016;7:79292\u2013304.","journal-title":"Oncotarget"},{"key":"7607_CR54","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.3390\/cancers15041050","volume":"15","author":"MC Nocito","year":"2023","unstructured":"Nocito MC, Avena P, Zavaglia L, De Luca A, Chimento A, Hamad T, et al. Adrenocortical carcinoma (ACC) cells rewire their metabolism to overcome curcumin antitumoral effects opening a window of opportunity to improve treatment. Cancers. 2023;15:1050.","journal-title":"Cancers"},{"key":"7607_CR55","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3390\/cancers14010214","volume":"14","author":"E Ricci","year":"2022","unstructured":"Ricci E, Fava M, Rizza P, Pellegrino M, Bonofiglio D, Casaburi I, et al. Foxo3a inhibits tamoxifen-resistant breast cancer progression by inducing integrin \u03b15 expression. Cancers. 2022;14:214.","journal-title":"Cancers"},{"key":"7607_CR56","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/nprot.2012.024","volume":"7","author":"M Yuan","year":"2012","unstructured":"Yuan M, Breitkopf SB, Yang X, Asara JM. A positive\/negative ion\u2013switching, targeted mass spectrometry\u2013based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue. Nat Protoc. 2012;7:872\u201381.","journal-title":"Nat Protoc"},{"key":"7607_CR57","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/s41592-021-01197-1","volume":"18","author":"S Alseekh","year":"2021","unstructured":"Alseekh S, Aharoni A, Brotman Y, Contrepois K, D\u2019auria J, Ewald J, et al. Mass spectrometry-based metabolomics: a guide for annotation, quantification and best reporting practices. Nat Methods. 2021;18:747\u201356.","journal-title":"Nat Methods"},{"key":"7607_CR58","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1038\/s41596-022-00710-w","volume":"17","author":"Z Pang","year":"2022","unstructured":"Pang Z, Zhou G, Ewald J, Chang L, Hacariz O, Basu N, et al. Using MetaboAnalyst 5.0 for LC\u2013HRMS spectra processing, multi-omics integration and covariate adjustment of global metabolomics data. Nat Protoc. 2022;17:1735\u201361.","journal-title":"Nat Protoc"},{"key":"7607_CR59","doi-asserted-by":"publisher","first-page":"W388","DOI":"10.1093\/nar\/gkab382","volume":"49","author":"Z Pang","year":"2021","unstructured":"Pang Z, Chong J, Zhou G, De Lima Morais DA, Chang L, Barrette M, et al. MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights. Nucleic Acids Res. 2021;49:W388\u201396.","journal-title":"Nucleic Acids Res"},{"key":"7607_CR60","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1093\/bioinformatics\/btq418","volume":"26","author":"J Xia","year":"2010","unstructured":"Xia J, Wishart DS. Valencia A. MetPA: a web-based metabolomics tool for pathway analysis and visualization. Bioinformatics. 2010;26:2342\u20134.","journal-title":"Bioinformatics"},{"key":"7607_CR61","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.ajpath.2012.05.026","volume":"181","author":"JH Heaton","year":"2012","unstructured":"Heaton JH, Wood MA, Kim AC, Lima LO, Barlaskar FM, Almeida MQ, et al. Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and \u03b2-catenin. Am J Pathol. 2012;181:1017\u201333.","journal-title":"Am J Pathol"},{"key":"7607_CR62","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/bioinformatics\/btg405","volume":"20","author":"L Gautier","year":"2004","unstructured":"Gautier L, Cope L, Bolstad BM, Irizarry RA. affy\u2014analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004;20:307\u201315.","journal-title":"Bioinformatics"},{"key":"7607_CR63","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ccell.2016.04.002","volume":"29","author":"S Zheng","year":"2016","unstructured":"Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, et al. Comprehensive Pan-genomic characterization of adrenocortical carcinoma. Cancer Cell. 2016;29:723\u201336.","journal-title":"Cancer Cell"},{"key":"7607_CR64","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1093\/nar\/gkv1507","volume":"44","author":"A Colaprico","year":"2016","unstructured":"Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, et al. TCGAbiolinks: an R\/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44:e71.","journal-title":"Nucleic Acids Res"},{"key":"7607_CR65","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139\u201340.","journal-title":"Bioinformatics"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07607-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07607-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07607-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T05:02:59Z","timestamp":1744606979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07607-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7607"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07607-y","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]},"assertion":[{"value":"5 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"291"}}